Immune Reconstitution Inflammatory
Syndrome (IRIS) Immune Reconstitution Inflammatory Syndrome (IRIS)
• French et al 1992 noted restoration of DTH within 6 months in 42% of a series of initially anergic individuals with HIV started on Zidovudine.
• In 4/9 with a maximal DTH response (>8mm), and one additional individual who developed a positive MAI PPD, an acute febrile illness developed within two weeks associated with localized MAI infection • They proposed that the restoration of immunity resulted in an acute inflammatory response to MAI antigens in tissues previously colonized French AH et al. AIDS 1992; 6:1293 -1297 Defining IRIS
• Shelburne et al proposed the term Immune Reconstitution Inflammatory Syndrome (IRIS) to represent a process in which clinical deterioration occurs shortly after initiation of HAART due to restoration of the capacity to mount an inflammatory immune response to either infectious or non-infectious antigens.
• They noted that in some cases the infectious agent was known to be present and under treatment prior to HAART initiation while in others, the infection was indolent but became apparent only after the inflammatory response developed • They reported a case in which Grave's disease developed following HAART in the absence of any new infection (and reviewed similar cases reported by others) suggesting that an auto-antigen could also incite the inflammatory response Shelburne SA, et al. Medicine 2002; 81:213-227 Two Types of IRIS
• Paradoxical /Delayed -Occurs in an individual following treatment and stabilization of a known infection at the time of immune reconstitution -Following initiation of HAART (typically w/in weeks to months) the infection appears to worsen in association with restoration of CD4+ T-lymphocyte counts, and reduction in HIV RNA plasma load -Histopathology demonstrates a vigorous inflammatory response in affected tissues in the absence of active infection
• In non-HIV-infected individuals, restoration of immune function can produce a similar pattern IRIS after Natalizumab Cessation ?
• Rebound MS activity following discontinuation of natalizumab therapy -Series of 32 patients without PML -38% RRMS, 25% SPMS patients relapsed -Marked inflammatory activity on MRI in excess of that seen in patients prior to starting natalizumab therapy -Diffuse inflammatory activity considered similar to that seen in PML-IRIS -MS activity suppressed by resumption of natalizumab therapy
• Case report: severe relapse 9 weeks after discontinuation of natalizumab for intended pursuit of pregnancy.
-Failure of response to multiple IVMP pulses led to PLEX followed by further worsening with multiple enhancing lesions. -CSF negative for JCV on 3 samples. -Biopsy revealed inflammatory demyelinating lesions, no PML.
-Patient reported to have ARR of 3-4 prior to starting natalizumab Miravalle A. Arch Neurol 2011; 68:186-191 Lenhard T et al. Neurology 2010; 75:831-833 Natalizumab -associated PML IRIS -Ag driven, influenced by T cell Receptor affinity; -Early immune restoration might bias to proliferation of memory effector cells
• Autoimmune Antigens -Lymphopenia / Homeostatic proliferation may predispose to autoimmune disorders with immune restoration due to epitope spreading or molecular mimicry -Inflammatory response directed at a self antigen difficult to distinguish from one directed at a persisting pathogenic antigen, both may occur 
Strikingly high numbers of plasma cells are found in MS-PML-IRIS lesions (a).
Lower numbers are present in inflammatory PML cases (b).
In MS-PML-IRIS, plasma cells are also evident in non-demyelinated white and grey matter (c, d) -Massive perivascular and parenchymal lymphomononuclear infiltrate -Majority of cells were HLA DR+ -T cell infiltrate contained 70% CD4+ and 24% CD8+; virtually all were CD45+RO+ memory cells -29% CD19+ Bcells; 86% were CD27/CD38 + memory B/plasma cells -Immunohistochemistry for JCV was negative, sparse in situ hypridization signals
• Ex vivo T cell cultures and CD4+ T cell clones were established -Brain derived CD4+ T cells were highly proliferative in response to VP1 peptides in contrast to those from CSF -CD4+ T cells: Th1= 46-53%, in brain and CSF -32.7% Brain derived CD4+ were bifunctional Th1-2 secreting both IFNγ & IL-4 -Found also in controls with PML, but not non-PML controls -Brain derived CD4+ T cells demonstrated JCV specific VP-1 response which was HLA restricted by DRB*15:01/B5*01:01. -VP1 contains epitopes recognized by both JCV specific CD4+ and CD8+ T cells Aly L. Brain 2011; 134:2687 -2702 Natalizumab associated PML IRIS CD4+ T lymphocytes
• Hypothesized: 
Diagnosis of IRIS in MS patients with Natalizumab associated PML
• The challenge is distinguishing worsening PML vs IRIS vs relapsing MS • Clinical context: emergence of worsening neurologic symptoms typically within weeks to a few months following a period of stability after withdrawal of NTZ.
• MRI typically shows enhancement and enlargement of the PML lesions, which may be associated with surrounding edema and mass effect, however there is no definite way to discriminate IRIS from worsening PML • In one study of 1H-MRS; Cho/Cr, mI/Cr, Lipid/lactate /Cr were increased and NAA/Cr decreased in PML-IRIS compared to PML without IRIS. Persistent elevation of mI/Cr ratio was seen with PML-IRIS. Combined lipid lactate peaks / Cr >1.5 when combined with contrast enhancement of lesions, was associated with a 79% probability of IRIS Normal perfusion Khoury MN, et al. Brain 2013; 136:3441-3450 Labeling modified Treating IRIS: Corticosteroids
Management of IRIS
• One RCT in HIV associated TB IRIS -Prednisone 1.5mg/kg/d for two weeks followed by 0.75mg/kg/d for two weeks was more effective than placebo in reducing days of hospitalization and need for outpatient procedures (combined primary endpoint) -Steroid group also had significantly greater improvements in symptoms, Karnofsky scores, and a QOL measure at two and four weeks, but not at later time points in the 12 week study.
• Some HIV-TB-IRIS patients experience recurrent symptoms when steroids tapered or withdrawn requiring therapy for months Meintjes G AIDS 2010; 24:2381 -2390 . Manabe YC, j Acquir Immune Defic Syndr 2007 46:456-462 Corticosteroid Treatment: Natalizumab Associated PML IRIS 
Summary
• IRIS is an exuberant immune response to an infectious or noninfectious antigen which, in the context of reversal of immune suppression, results in clinical deterioration not due to worsening of the infection or primary immune process • The extent of immune suppression, the rate and extent of the reversal, antigen load, and possibly susceptibility factors including host and pathogen genetics, and effects of antimicrobial therapy may influence the occurrence, nature and extent of the inflammatory response • IRIS has the capacity to cause substantial tissue damage with consequent morbidity and mortality • The clinical challenge in MS patients is to discriminate IRIS from inadequately treated infection or relapsing MS • IRIS may persist for lengthy periods requiring prolonged monitoring and therapeutic intervention
